Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose ipilimumab monotherapy in previously treated unresectable stage III/IV melanoma
2005-003265-16Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ipilimumab in melanoma (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Best overall response rate (BORR) and Dose-response relationship based on BORR. Started Mar 2006; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2005-003265-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003265-16.